Biotech Deal Frenzy Continues with Merck’s Acquisition of Cidara Therapeutics
Merck made headlines last week with its announcement of a $9.2 billion deal to acquire biotech company Cidara Therapeutics. The main attraction for Merck was Cidara’s antiviral drug, currently in late-stage clinical trials, designed to prevent flu infections in high-risk patients. This acquisition marks Merck’s second multi-billion dollar deal this year, following its $10 billion agreement to purchase Verona Pharma for its respiratory drugs back in July.
The biotech industry has been experiencing a deal frenzy this year, with major acquisitions like Pfizer’s $10 billion takeover of Metsera and Johnson & Johnson’s $3 billion deal to acquire Halda Therapeutics for its cancer therapies. According to accounting firm EY, the total value of mergers and acquisitions in the biotech sector has already reached $129 billion through October 31, surpassing the total for all of 2024. Interestingly, despite fewer deals being made this year compared to last year, the average deal size has increased by 101%, reflecting a shift towards market-ready assets.
Recursion’s New CEO Takes on the Challenge of AI Drug Development
Recursion, a company that uses artificial intelligence in drug discovery, has faced challenges in bringing its drugs to market since its founding in 2014. Despite its ambitious goal of developing 100 drugs in 10 years, the company has yet to see a drug reach commercialization. Share prices have plummeted, workforce layoffs have occurred, and financial losses have mounted. However, incoming CEO Najat Khan remains optimistic about the company’s future, emphasizing the importance of tackling the high failure rate in drug development.
Baby Formula Botulism Outbreak Raises Concerns
ByHeart, a company known for its organic infant formula, recently faced a botulism outbreak that affected 23 babies across 13 states. The outbreak led to hospitalizations and prompted several lawsuits from affected families. ByHeart’s manufacturing plant in Pennsylvania was shut down earlier this year due to safety violations, including mold and insect infestations. The company issued a nationwide recall of its infant formula in response to the outbreak.
The incident comes at a time when the organic infant formula market is gaining popularity, driven by consumer demand for healthier options. However, the outbreak serves as a reminder of the importance of stringent safety measures in food production facilities.
Profluent Raises $106 Million in Venture Funding for AI Protein Design
Profluent, a startup based in Emeryville, California, has developed AI models that enable scientists to design novel proteins with specific properties. The company’s technology allows researchers to input desired protein characteristics and receive a DNA recipe for creating the protein. Profluent recently raised $106 million in new venture funding, led by Jeff Bezos’s Bezos Expeditions and Altimeter Capital, bringing its total investment to $150 million. The funding will support the company’s efforts to unlock new drug discovery and agricultural solutions through protein design.
In conclusion, the biotech industry continues to see significant deal activity, with major acquisitions and partnerships driving innovation and growth. Companies like Merck and Profluent are at the forefront of developing cutting-edge treatments and technologies that have the potential to revolutionize healthcare and agriculture. Despite challenges and setbacks, the industry remains resilient and focused on advancing scientific breakthroughs for the benefit of society.
